The Hematologist offers podcasts that enhance the reading experience by presenting key results and additional insights from published articles in a convenient audio format. All of the podcasts are available for FREE! Learn more.
Where to Listen
Listen to the podcasts below (Internet connection required) or download and listen to them later via Spotify, Apple Podcasts, or wherever you find your podcasts.
Growing the Next Generation of Hematologists
April 15, 2024
Speakers: Shaji Kumar, MD, Leslie Elllis, MD
In this episode, Editor-in-Chief Shaji Kumar, MD, a professor of medicine at Mayo Clinic in Rochester, Minnesota, talks with Leslie Ellis, MD, a professor of internal medicine at Atrium Health Wake Forest Baptist in Winston Salem, North Carolina. They discuss the ASH Ambassador Program, which is designed to support the recruitment and retention of trainees into hematology. Dr. Ellis is chair of an ASH oversight subcommittee for that program.
Women in Hematology
March 26, 2024
Speakers: Dr. Tamara Dunn; Dr. Toyosi Onwuemene; Dr. Nina Shah
In this episode, Tamara Dunn, MD, a clinical associate professor of medicine in the division of hematology at Stanford University in Stanford, California, and co-chair of ASH’s Women in Hematology Working Group, hosts a conversation with Toyosi Onwuemene, MD, an associate professor of medicine, specializing in hemostasis/thrombosis, at Duke University in Durham, North Carolina, and Nina Shah, MD, the global clinical head for multiple myeloma research and development at AstraZeneca. They talk about career choices and opportunities for women in hematology, both in academic medicine and industry. Support for this episode provided by Sanofi.
Four Is Better Than Three: Will We Finally Agree?
March 18, 2024
Speakers: Ajai Chari, MD, and Pieter Sonneveld, MD, PhD
In this episode, Contributing Editor Ajai Chari, MD, a professor of clinical medicine and director of the myeloma program at the University of California San Francisco, talks with Pieter Sonneveld, MD, PhD, a professor of hematology at the Erasmus University of Rotterdam in the Netherlands. They discuss Dr. Sonneveld’s recent paper, “Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma,” published in The New England Journal of Medicine. (Disclosures: Dr. Chari has received consulting fees from Abbvie, Adaptive, Amgen, Antengene, Bristol Myers Squibb, Forus, Genentech/Roche, Glaxo Smith Klein, Janssen, Karyopharm, Millenium/Takeda, and Sanofi/Genzyme, and he received research funding from Janssen. Dr. Sonneveld has received research funding from and serves on advisory boards for Amgen, Bristol Myers Squibb, Celgene, Janssen, Karyopharm, and he serves on a Pfizer advisory board.)
The Hematologist: ASH News and Reports
Advertisement
